Page last updated: 2024-12-05

2-(2'-hydroxyphenyl)benzoxazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-(2'-hydroxyphenyl)benzoxazole, also known as 2-(2-hydroxyphenyl)-1,3-benzoxazole or HBO, is an organic compound. It is a white solid that is soluble in ethanol. HBO has been studied for its potential applications in various fields, including:
* **Fluorescence:** HBO exhibits fluorescence properties and has been investigated for its use in fluorescent probes, sensors, and organic light-emitting diodes (OLEDs).
* **Photoluminescence:** HBO's photoluminescent properties have been utilized in organic photovoltaics (OPVs), where it acts as a light-emitting material.
* **Materials Science:** HBO has been explored for its potential as a material in the development of organic thin-film transistors (OTFTs) due to its semiconducting properties.
* **Medicinal Chemistry:** HBO derivatives have shown potential biological activity, particularly in areas like anti-inflammatory and anticancer drug development.
* **Chemosensor:** HBO has been utilized as a chemosensor for the detection of various metal ions, including copper (Cu2+) and zinc (Zn2+).
* **Organic Chemistry:** HBO serves as a building block for the synthesis of more complex organic molecules and materials.
The synthesis of HBO often involves the condensation reaction between o-aminophenol and salicylaldehyde, followed by cyclization. The specific synthetic pathways and conditions can vary depending on the desired purity and scale of production.
'

2-(2'-hydroxyphenyl)benzoxazole: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-(1,3-benzoxazol-2-yl)phenol : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazole substituted by a 2-hydroxyphenyl group at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID13269
CHEMBL ID1650631
CHEBI ID180630
SCHEMBL ID56592
SCHEMBL ID11984913
MeSH IDM0397030

Synonyms (58)

Synonym
rg8gw8ksu5 ,
4-27-00-02080 (beilstein handbook reference)
unii-rg8gw8ksu5
o-2-benzoxazolylphenol
CHEBI:180630
2-(benzo[d]oxazol-2-yl)phenol
o-(2-benzoxazolyl)phenol
2-(2'-hydroxylphenyl)benzoxazole
2-benzooxazol-2-yl-phenol
2-(2-benzoxazolyl)phenol
2-(2'-hydroxyphenyl)benzoxazole
2-(1,3-benzoxazol-2-yl)phenol
835-64-3
nsc5423
wln: t56 bn doj cr bq
usaf ek-6754
phenol, 2-(2-benzoxazolyl)-
phenol, o-2-benzoxazolyl-
nsc-5423
2-(2-hydroxyphenyl)benzoxazole
2-(o-hydroxyphenyl)benzoxazole
ENAMINE_005881
nsc 403545
brn 0173017
ccris 7875
nsc 5423
einecs 212-642-0
2-benzoxazol-2-ylphenol
IDI1_008116
nsc-403545
nsc403545
EU-0033400
2-(2-hydroxyphenyl)benzoxazole, 98%
OPREA1_077278
HMS1410L07
AKOS000669321
H0291
CHEMBL1650631
STK731652
CCG-103213
FT-0608486
SCHEMBL56592
DTXSID4061200
2-(o-hydroxyphenyl)benzoxazol
2-(ortho-hydroxyphenyl)-benzoxazole
2-(o-hydroxy phenyl)benzoxazole
SCHEMBL11984913
sr-01000389308
SR-01000389308-1
mfcd00005767
AS-59719
2-(2-hydroxyphenyl)-1,3-benzoxazole
BRD-K11826754-001-02-4
D71022
A855538
SY077623
CS-W015057
Z56756575
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
1,3-benzoxazolesCompounds based on a fused 1,3-oxazole and benzene bicyclic ring skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1633634Inhibition of recombinant human JMJD3 expressed in baculovirus infected Sf9 cells at 25 uM using biotinylated histone H3 peptide as substrate incubated for 15 mins followed by substrate addition and measured after 60 mins by AlphaScreen assay relative to 2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Identification of the 2-Benzoxazol-2-yl-phenol Scaffold as New Hit for JMJD3 Inhibition.
AID1058855Inhibition of human COX2 using arachidonic acid as substrate assessed as formation of TMPD at 50 uM incubated for 5 mins prior to substrate addition measured after 5 mins by spectrophotometry2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Discovery of a novel activator of 5-lipoxygenase from an anacardic acid derived compound collection.
AID1917873Antiproliferative activity against human U-251MG cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay2022Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20
Recent Scaffold Hopping Applications in Central Nervous System Drug Discovery.
AID566706Inhibition of human recombinant MMP9 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566699Inhibition of mushroom tyrosinase at 1 mM after 10 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1571460Antiproliferative activity against human U251MG cells after 72 hrs by sulforhodamine B assay2018MedChemComm, Nov-01, Volume: 9, Issue:11
Towards identifying potent new hits for glioblastoma.
AID1571463Antiproliferative activity against human IN1760 cells after 72 hrs by sulforhodamine B assay2018MedChemComm, Nov-01, Volume: 9, Issue:11
Towards identifying potent new hits for glioblastoma.
AID566704Inhibition of human recombinant MMP3 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1917875Antiproliferative activity against human IN1760 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay2022Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20
Recent Scaffold Hopping Applications in Central Nervous System Drug Discovery.
AID1571459Antiproliferative activity against human U87MG cells after 72 hrs by sulforhodamine B assay2018MedChemComm, Nov-01, Volume: 9, Issue:11
Towards identifying potent new hits for glioblastoma.
AID1571462Antiproliferative activity against human IN1528 cells after 72 hrs by sulforhodamine B assay2018MedChemComm, Nov-01, Volume: 9, Issue:11
Towards identifying potent new hits for glioblastoma.
AID566702Inhibition of human recombinant MMP1 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1058856Inhibition of human 5-LOX using lionleic acid as substrate assessed as formation of 13-HPOD at 50 uM incubated for 10 mins prior to substrate addition measured after 10 secs by UV absorbance assay2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Discovery of a novel activator of 5-lipoxygenase from an anacardic acid derived compound collection.
AID1571461Antiproliferative activity against human IN1472 cells after 72 hrs by sulforhodamine B assay2018MedChemComm, Nov-01, Volume: 9, Issue:11
Towards identifying potent new hits for glioblastoma.
AID566701Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566703Inhibition of human recombinant MMP2 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1917872Antiproliferative activity against human U-87 MG cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay2022Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20
Recent Scaffold Hopping Applications in Central Nervous System Drug Discovery.
AID566705Inhibition of human recombinant MMP8 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (20.00)29.6817
2010's14 (70.00)24.3611
2020's2 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.47 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.89 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]